A world-leading researcher in solid electrolytes and sophisticated electron microscopy methods received Oak Ridge National Laboratory’s top science honor today for her work in developing new materials for batteries. The announcement was made during a livestreamed Director’s Awards event hosted by ORNL Director Thomas Zacharia.
Ten scientists from the Department of Energy’s Oak Ridge National Laboratory are among the world’s most highly cited researchers, according to a bibliometric analysis conducted by the scientific publication analytics firm Clarivate.
The U.S. Department of Energy’s Office of Science announced allocations of supercomputer access to 51 high-impact computational science projects for 2022 through its Innovative and Novel Computational Impact on Theory and Experiment, or INCITE, program.
A team including researchers from the Department of Energy’s Oak Ridge National Laboratory has developed a digital tool to better monitor a condition known as Barrett’s esophagus, which affects more than 3 million people in the United States.
ORNL's Larry Baylor and Andrew Lupini have been elected fellows of the American Physical Society.
L&N STEM Academy senior Tyler Duckworth has been named recipient of the 2021 UT-Battelle Scholarship to attend the University of Tennessee.
Sergei Kalinin, a scientist and inventor at the Department of Energy’s Oak Ridge National Laboratory, has been elected a fellow of the Microscopy Society of America professional society.
The Department of Energy’s Oak Ridge National Laboratory has licensed its award-winning artificial intelligence software system, the Multinode Evolutionary Neural Networks for Deep Learning, to General Motors for use in vehicle technology and design.
The U.S. Department of Energy’s Innovative and Novel Computational Impact on Theory and Experiment, or INCITE, program is seeking proposals for high-impact, computationally intensive research campaigns in a broad array of science, engineering and computer science domains.
A rare isotope in high demand for treating cancer is now more available to pharmaceutical companies developing and testing new drugs.